278 related articles for article (PubMed ID: 11729351)
1. A Th1-inducing adjuvant, MPL, enhances antibody profiles in experimental animals suggesting it has the potential to improve the efficacy of allergy vaccines.
Wheeler AW; Marshall JS; Ulrich JT
Int Arch Allergy Immunol; 2001 Oct; 126(2):135-9. PubMed ID: 11729351
[TBL] [Abstract][Full Text] [Related]
2. Standardisation of glutaraldehyde-modified tyrosine-adsorbed tree pollen vaccines containing the Th1-inducing adjuvant, monophosphoryl lipid A (MPL).
Hopkins M; Lees BG; Richardson DG; Woroniecki SR; Wheeler AW
Allergol Immunopathol (Madr); 2001; 29(6):245-54. PubMed ID: 11834183
[TBL] [Abstract][Full Text] [Related]
3. A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections.
Drachenberg KJ; Wheeler AW; Stuebner P; Horak F
Allergy; 2001 Jun; 56(6):498-505. PubMed ID: 11421893
[TBL] [Abstract][Full Text] [Related]
4. Allergoid-specific T-cell reaction as a measure of the immunological response to specific immunotherapy (SIT) with a Th1-adjuvanted allergy vaccine.
von Baehr V; Hermes A; von Baehr R; Scherf HP; Volk HD; Fischer von Weikersthal-Drachenberg KJ; Woroniecki S
J Investig Allergol Clin Immunol; 2005; 15(4):234-41. PubMed ID: 16433203
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of short-term specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A (MPL) for children and adolescents.
Drachenberg KJ; Heinzkill M; Urban E; Woroniecki SR
Allergol Immunopathol (Madr); 2003; 31(5):270-7. PubMed ID: 14572416
[TBL] [Abstract][Full Text] [Related]
6. Pollinex Quattro Ragweed: safety evaluation of a new allergy vaccine adjuvanted with monophosphoryl lipid A (MPL) for the treatment of ragweed pollen allergy.
Baldrick P; Richardson D; Woroniecki SR; Lees B
J Appl Toxicol; 2007; 27(4):399-409. PubMed ID: 17299813
[TBL] [Abstract][Full Text] [Related]
7. Ultra-short-course seasonal allergy vaccine (Pollinex Quattro).
McCormack PL; Wagstaff AJ
Drugs; 2006; 66(7):931-8. PubMed ID: 16740007
[TBL] [Abstract][Full Text] [Related]
8. The adsorption of allergoids and 3-O-desacyl-4'-monophosphoryl lipid A (MPL®) to microcrystalline tyrosine (MCT) in formulations for use in allergy immunotherapy.
Bell AJ; Heath MD; Hewings SJ; Skinner MA
J Inorg Biochem; 2015 Nov; 152():147-53. PubMed ID: 26337118
[TBL] [Abstract][Full Text] [Related]
9. Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies.
Mothes N; Heinzkill M; Drachenberg KJ; Sperr WR; Krauth MT; Majlesi Y; Semper H; Valent P; Niederberger V; Kraft D; Valenta R
Clin Exp Allergy; 2003 Sep; 33(9):1198-208. PubMed ID: 12956739
[TBL] [Abstract][Full Text] [Related]
10. Safety evaluation of a new allergy vaccine containing the adjuvant monophosphoryl lipid A (MPL) for the treatment of grass pollen allergy.
Baldrick P; Richardson D; Wheeler AW; Woroniecki SR
J Appl Toxicol; 2004; 24(4):261-8. PubMed ID: 15300713
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of a short course of specific immunotherapy in patients with allergic rhinoconjunctivitis to ragweed pollen.
Patel P; Holdich T; Fischer von Weikersthal-Drachenberg KJ; Huber B
J Allergy Clin Immunol; 2014 Jan; 133(1):121-9.e1-2. PubMed ID: 23870670
[TBL] [Abstract][Full Text] [Related]
12. Monophosphoryl lipid A (MPL) promotes allergen-induced immune deviation in favour of Th1 responses.
Puggioni F; Durham SR; Francis JN
Allergy; 2005 May; 60(5):678-84. PubMed ID: 15813815
[TBL] [Abstract][Full Text] [Related]
13. Allergy vaccines--new approaches to an old concept.
Wheeler AW; Woroniecki SR
Expert Opin Biol Ther; 2004 Sep; 4(9):1473-81. PubMed ID: 15335314
[TBL] [Abstract][Full Text] [Related]
14. Comparative study of adjuvants for allergen-specific immunotherapy in a murine model.
de la Torre MV; Baeza ML; Nájera L; Zubeldia JM
Immunotherapy; 2018 Oct; 10(14):1219-1228. PubMed ID: 30244623
[TBL] [Abstract][Full Text] [Related]
15. Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results.
Cluff CW
Adv Exp Med Biol; 2010; 667():111-23. PubMed ID: 20665204
[TBL] [Abstract][Full Text] [Related]
16. Monophosphoryl lipid A enhances both humoral and cell-mediated immune responses to DNA vaccination against human immunodeficiency virus type 1.
Sasaki S; Tsuji T; Hamajima K; Fukushima J; Ishii N; Kaneko T; Xin KQ; Mohri H; Aoki I; Okubo T; Nishioka K; Okuda K
Infect Immun; 1997 Sep; 65(9):3520-8. PubMed ID: 9284115
[TBL] [Abstract][Full Text] [Related]
17. Vaccine adjuvants CpG (oligodeoxynucleotides ODNs), MPL (3-O-deacylated monophosphoryl lipid A) and naloxone-enhanced Th1 immune response to the Plasmodium vivax recombinant thrombospondin-related adhesive protein (TRAP) in mice.
Nazeri S; Zakeri S; Mehrizi AA; Djadid ND; Snounou G; Andolina C; Nosten F
Med Microbiol Immunol; 2018 Nov; 207(5-6):271-286. PubMed ID: 29948091
[TBL] [Abstract][Full Text] [Related]
18. OVA-bound nanoparticles induce OVA-specific IgG1, IgG2a, and IgG2b responses with low IgE synthesis.
Yanase N; Toyota H; Hata K; Yagyu S; Seki T; Harada M; Kato Y; Mizuguchi J
Vaccine; 2014 Oct; 32(45):5918-24. PubMed ID: 25211769
[TBL] [Abstract][Full Text] [Related]
19. A Fusion Protein Consisting of the Vaccine Adjuvant Monophosphoryl Lipid A and the Allergen Ovalbumin Boosts Allergen-Specific Th1, Th2, and Th17 Responses In Vitro.
Schülke S; Vogel L; Junker AC; Hanschmann KM; Flaczyk A; Vieths S; Scheurer S
J Immunol Res; 2016; 2016():4156456. PubMed ID: 27340679
[TBL] [Abstract][Full Text] [Related]
20. The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1.
Moore A; McCarthy L; Mills KH
Vaccine; 1999 Jun; 17(20-21):2517-27. PubMed ID: 10418898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
